JP2017526695A5 - - Google Patents

Download PDF

Info

Publication number
JP2017526695A5
JP2017526695A5 JP2017512679A JP2017512679A JP2017526695A5 JP 2017526695 A5 JP2017526695 A5 JP 2017526695A5 JP 2017512679 A JP2017512679 A JP 2017512679A JP 2017512679 A JP2017512679 A JP 2017512679A JP 2017526695 A5 JP2017526695 A5 JP 2017526695A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
patient
composition according
anamorelin
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017512679A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526695A (ja
JP6356907B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/047435 external-priority patent/WO2016036598A1/en
Publication of JP2017526695A publication Critical patent/JP2017526695A/ja
Publication of JP2017526695A5 publication Critical patent/JP2017526695A5/ja
Priority to JP2018113592A priority Critical patent/JP6923486B2/ja
Application granted granted Critical
Publication of JP6356907B2 publication Critical patent/JP6356907B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017512679A 2014-09-04 2015-08-28 アナモレリンに基づく医療 Active JP6356907B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018113592A JP6923486B2 (ja) 2014-09-04 2018-06-14 アナモレリンに基づく医療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462045976P 2014-09-04 2014-09-04
US62/045,976 2014-09-04
PCT/US2015/047435 WO2016036598A1 (en) 2014-09-04 2015-08-28 Medical treatments based on anamorelin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018113592A Division JP6923486B2 (ja) 2014-09-04 2018-06-14 アナモレリンに基づく医療

Publications (3)

Publication Number Publication Date
JP2017526695A JP2017526695A (ja) 2017-09-14
JP2017526695A5 true JP2017526695A5 (OSRAM) 2017-10-26
JP6356907B2 JP6356907B2 (ja) 2018-07-11

Family

ID=55436476

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017512679A Active JP6356907B2 (ja) 2014-09-04 2015-08-28 アナモレリンに基づく医療
JP2018113592A Active JP6923486B2 (ja) 2014-09-04 2018-06-14 アナモレリンに基づく医療
JP2021029775A Active JP7044918B2 (ja) 2014-09-04 2021-02-26 アナモレリンに基づく医療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018113592A Active JP6923486B2 (ja) 2014-09-04 2018-06-14 アナモレリンに基づく医療
JP2021029775A Active JP7044918B2 (ja) 2014-09-04 2021-02-26 アナモレリンに基づく医療

Country Status (44)

Country Link
US (5) US9675600B2 (OSRAM)
EP (2) EP3188599B1 (OSRAM)
JP (3) JP6356907B2 (OSRAM)
KR (3) KR102307275B1 (OSRAM)
CN (5) CN109172575A (OSRAM)
AP (1) AP2017009772A0 (OSRAM)
AR (1) AR103118A1 (OSRAM)
AU (1) AU2015312231B2 (OSRAM)
BR (1) BR112017003552A2 (OSRAM)
CA (1) CA2959158A1 (OSRAM)
CL (1) CL2017000494A1 (OSRAM)
CO (1) CO2017003263A2 (OSRAM)
CR (1) CR20170121A (OSRAM)
CY (1) CY1122746T1 (OSRAM)
DK (1) DK3188599T3 (OSRAM)
DO (1) DOP2017000055A (OSRAM)
EA (1) EA035578B1 (OSRAM)
EC (1) ECSP17019893A (OSRAM)
ES (1) ES2761777T3 (OSRAM)
GE (2) GEP20186939B (OSRAM)
HR (1) HRP20192345T1 (OSRAM)
HU (1) HUE046894T2 (OSRAM)
IL (1) IL250692B (OSRAM)
JO (1) JO3541B1 (OSRAM)
LT (1) LT3188599T (OSRAM)
MA (1) MA40607B1 (OSRAM)
MD (1) MD4710C1 (OSRAM)
ME (1) ME03597B (OSRAM)
MX (1) MX361741B (OSRAM)
MY (1) MY187167A (OSRAM)
NI (1) NI201700024A (OSRAM)
PE (1) PE20171109A1 (OSRAM)
PH (1) PH12017500392B1 (OSRAM)
PL (1) PL3188599T3 (OSRAM)
PT (1) PT3188599T (OSRAM)
RS (1) RS59751B1 (OSRAM)
SG (1) SG11201701567UA (OSRAM)
SI (1) SI3188599T1 (OSRAM)
SV (1) SV2017005400A (OSRAM)
TN (1) TN2017000040A1 (OSRAM)
TW (1) TWI639429B (OSRAM)
UA (1) UA120765C2 (OSRAM)
UY (1) UY36286A (OSRAM)
WO (1) WO2016036598A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
GEP20186939B (en) 2014-09-04 2018-12-25 Healthcare Sa Helsinn Medical treatments based on anamorelin
EP3836801A4 (en) 2018-08-16 2022-05-18 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
WO2020132341A1 (en) 2018-12-20 2020-06-25 Aimmune Therapeutics, Inc. Peanut oral immunotherapy dosing schedule for missed doses
CA3137295A1 (en) 2019-05-10 2020-11-19 Aimmune Therapeutics, Inc. Methods for improving the quality of life of a patient with a peanut allergy
BR112022002767A2 (pt) 2019-08-30 2022-05-10 Helsinn Healthcare Sa Métodos de fabricação de um comprimido de cloridrato de anamorelina, comprimidos e método para melhorar um ou mais sintomas de caquexia de câncer
WO2021079978A1 (ja) * 2019-10-24 2021-04-29 東レ株式会社 悪液質の治療剤又は予防剤
JP2024534464A (ja) * 2021-09-17 2024-09-20 小野薬品工業株式会社 食欲不振／悪液質患者における患者報告アウトカムに関する臨床的に意味のある改善を判定し、提供する方法
WO2025004650A1 (ja) * 2023-06-28 2025-01-02 日清オイリオグループ株式会社 中高年者の疲労感を軽減するための剤及び組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
ECSP993020A (es) 1999-06-16 1999-08-12 Terapia de combinacion para la fragilidad musculoesqueletica
ECSP993021A (es) 1999-06-16 1999-08-12 Combinaciones terapeuticas para la fragilidad musculoesqueletica
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
CN1863550A (zh) * 2003-08-06 2006-11-15 加斯特罗泰克药物公司 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用
WO2005014032A2 (en) 2003-08-06 2005-02-17 Gastrotech Pharma A/S Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
KR20070010151A (ko) 2004-03-30 2007-01-22 사파이어 세라퓨틱스, 인크. 성장 호르몬 분비촉진제를 이용하여 ｃ-반응성 단백질을감소시키는 방법
EP2298760B1 (en) * 2004-06-29 2015-08-05 Helsinn Healthcare S.A. Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
MX2009008561A (es) * 2007-02-13 2010-01-15 Helsinn Therapeutics Us Inc Metodo para tratar trastornos proliferativos celulares utilizando secretagogos.
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
JO3353B1 (ar) * 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
CN104470524A (zh) * 2012-05-25 2015-03-25 拉夸里亚创药株式会社 用于治疗胃酸缺乏症的生长激素释放肽受体激动剂
GEP20186939B (en) 2014-09-04 2018-12-25 Healthcare Sa Helsinn Medical treatments based on anamorelin

Similar Documents

Publication Publication Date Title
JP2017526695A5 (OSRAM)
JP2019503365A5 (OSRAM)
FI3849534T3 (fi) Yhdistelmähoidot
EA201170018A1 (ru) Разагилин для изменения течения болезни паркинсона
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
MX2021002322A (es) Nuevos metodos.
JP2016528162A5 (OSRAM)
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
JP2015505564A5 (OSRAM)
HRP20250615T1 (hr) Tradipitant za upotrebu u liječenju gastropareze
JP2016147915A5 (OSRAM)
JP2016512817A5 (OSRAM)
HK1202776A1 (en) Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy
TN2012000046A1 (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorfers
JP2018090566A5 (OSRAM)
HRP20192345T1 (hr) Medicinski tretmani na bazi anamorelina
JP2014508758A5 (OSRAM)
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
MX2023001014A (es) Composiciones farmaceuticas que comprenden venglustat.
MX2021001563A (es) Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.
JP2017526693A5 (OSRAM)
MX2022013450A (es) Formulaciones farmaceuticas.